A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OPERA® FOR REDUCING TREATMENT DISCONTINUATION IN RESECTED COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY

di Prof. S. Cascinu – Division of Oncology, University Hospital of Modena

Study Objective(s):

Primary: To evaluate the efficacy of Opera® in preventing oxaliplatin dose reductions, cycles delays and patient withdraw in patients receiving oxaliplatin-containing adjuvant chemotherapy for resected colorectal cancer

Secondary: To evaluate the impact of Opera® on treatment efficacy.

Sottoposto al comitato etico.